★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★Open research. Global perspectives.
editor@theamericanjournals.comPublisher Home ↗
Medical Science OPEN ACCESS

DEVELOPMENT AND VALIDATION OF AN RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF COBICISTAT AND ATAZANAVIR IN BULK AND PHARMACEUTICAL DOSAGE FORM

G Ravikumar
Professor in Dept. Of Physical Chemistry, Osmania University, Hyderabad, Telangana, India
DOI Crossref DOI 10.37547/TAJMSPR/Volume05Issue09-01
tajmspr 2023
VOL. 5 / NO. 09 SEPTEMBER
FULL TEXT PP. 01-04
DOWNLOAD PDF

View all articles in this issue ↗

VOLUME 5
ISSUE 09
YEAR 2023
PAGES 01-04
RESEARCH OVERVIEW

Abstract

This research paper focuses on the development and validation of an RP-HPLC (Reverse-Phase High-Performance Liquid Chromatography) method for the simultaneous estimation of cobicistat and atazanavir in bulk and pharmaceutical dosage form. Cobicistat and atazanavir are important antiretroviral drugs used in the treatment of HIV infection. The development of a reliable and accurate analytical method for their simultaneous determination is essential for quality control and pharmacokinetic studies. The RP-HPLC method was optimized by considering factors such as column selection, mobile phase composition, flow rate, and detection wavelength. Validation parameters including linearity, precision, accuracy, specificity, robustness, and system suitability were evaluated according to international guidelines. The developed method demonstrated good linearity, sensitivity, and selectivity for the simultaneous estimation of cobicistat and atazanavir in both bulk and pharmaceutical dosage form. The findings of this study provide a robust and reliable analytical method that can be utilized for routine analysis and quality control of cobicistat and atazanavir formulations.

RESEARCH TOPICS

Keywords

RP-HPLC Cobicistat Atazanavir

Downloads

Download data is not yet available.
SOURCES & SCHOLARSHIP

References

  1. http://en.wikipedia.org/wiki/Cobicistat.
  2. http://www.drugs.com/mtm/cobicistat.html.
  3. http://en.wikipedia.org/wiki/atazanavir
  4. http://www.drugs.com/cdi/atazanavir.html.
  5. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206353s000lbl.pdf.
  6. Eve-Irene Lepist Et al., Cobicistat Booststhe Intestinal Absorption of TransportSubstrates, Including HIV Protease Inhibitorsand GS-7340, In Vitr, Antimicrobial AgentsChemother., Vol 56(10), pg 5409-5413. oct2012.
  7. 7. Kavitha K, Geetha Y, Hariprasad G,Venkatnarayana R and Subramanian R(Jan, 2013) “Development and Validation ofRp-hplc Analytical Method For SimultaneousEstimation of Emtricitabine, Rilpivirine,Tenofovir Disoproxil Fumarate And ItsPharmaceutical Dosage Forms”, AcademicJournal Pharmacie Globale, [Online], Vol. 4No. 1, P. 1.
  8. Charushila H B and Shivanand N H (2013),Stability Indicating RP-HPLC Method for theDetermination of Atazanavir Sulphate in Bulkand Dosage Form”, Drug Invention Today,Vol. 5, pp. 81-86.
  9. Reddy B V, Jyothi G, Reddy B S, Raman NV, Reddy K S and Rambabu C (2013),Stability-indicating HPLC Method for theDetermination of Darunavir Ethanolate”, JChromatogr Sci., Vol. 51, pp. 471-476.
  10. Tulsidas Mishra and Pranav S S (2014),“Validation of Simultaneous QuantitativeMethod of HIV Protease Inhibitors Atazanavir,Darunavir and Ritonavir in Human Plasmaby UPLCMS/MS”, The Scientific WorldJournal, pp. 1-12.